ArticleYonsei medical journal2026
Differential Associations of Lipid Profiles with Dementia and Cardiovascular Disease: Findings from the UK Biobank Cohort.
Article in Yonsei medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeLowering low-density lipoprotein cholesterol (LDL-C) is crucial for cardiovascular disease (CVD) prevention, but its impact on cognitive function-and the potential differences by dementia subtype and cholesterol-lowering medication use-remain unclear. This study aimed to examine the associations between lipid levels and dementia and CVD risks, considering dementia subtypes and cholesterol-lowering medication use. MATERIALS AND
methodsA prospective cohort study was conducted using UK Biobank data. Serum lipid levels, including LDL-C, high-density lipoprotein cholesterol (HDL-C), triglycerides, total cholesterol, and remnant cholesterol, were categorized into clinically relevant ranges. Accounting for cholesterol-lowering medication use, the primary outcomes were incident all-cause dementia, Alzheimer's dementia (AD), vascular dementia (VD), and CVD.
resultsHigh LDL-C (≥160 mg/dL) increased AD risk across all groups {hazard ratio (HR): 1.23 [95% confidence interval (CI): 1.10-1.38],
conclusionThis study underscores the differential associations of lipid levels with dementia and CVD risk, depending on dementia subtype and cholesterol-lowering medication use. High LDL-C was linked to increased AD risk, whereas low LDL-C was linked to increased VD risk in those not taking cholesterol-lowering medication.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.